ReviewThe Journal of infectious diseases2020
Antimicrobial Treatment Duration in Sepsis and Serious Infections.
Review in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections.Infection · 2026Article
- Development and Validation of a Nomogram for Mortality Prediction in Septic Patients with Prolonged or Chronic Critical Illness.Diagnostics (Basel, Switzerland) · 2026Article
- Early ΔNLR Outperforms Baseline Inflammatory Markers in Predicting Short-Term Outcomes in Sepsis.Diagnostics (Basel, Switzerland) · 2026Article
- Short- versus long-course antibiotic therapy in mechanically ventilated sepsis patients with pneumonia: a real-world cohort analysis.Clinics (Sao Paulo, Brazil) · 2026Article
- Seven versus Fourteen Days of Antibiotics for Gram-Negative Bacteremia from a Urinary Tract Source: a Systematic Review and Meta-analysis.Infectious diseases and therapy · 2026Article
- Micro/nanorobotics for sepsis diagnosis and therapy: a frontier in precision medicine.Theranostics · 2026Review
- Rapid culture-free diagnosis of clinical pathogens via integrated microfluidic-Raman micro-spectroscopy.Nature communications · 2025Article
- An enhanced nutrition support system is associated with greater adequacy of enteral nutrition in long-term ICU patients: a retrospective cohort study.BMC nutrition · 2025Article
- Shorter versus longer-duration antibiotic treatments for immunocompetent patients with bloodstream infections: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Exploring the Impact of Chemotherapy on the Emergence of Antibiotic Resistance in the Gut Microbiota of Colorectal Cancer Patients.Antibiotics (Basel, Switzerland) · 2025Review
- The Therapeutic Potential of Exosome Therapy in Sepsis Management: Addressing Complications and Improving Outcomes".Cell biochemistry and biophysics · 2025Review
- Agar-Dilution Is Comparable to Broth Dilution for MIC Determination inAntibiotics (Basel, Switzerland) · 2025Article
- Observational
- Association between in-hospital antibiotic use and long-term outcomes in critically ill patients.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Investigation of the Significance of Blood Signatures on Sepsis-Induced Acute Lung Injury in Sepsis Within 24 Hours.International journal of genomics · 2025Article
- Clinical management of sepsis-associated acute respiratory distress syndrome: current evidence and future directions.Frontiers in medicine · 2025Review
- Th17/Treg balance: the bloom and wane in the pathophysiology of sepsis.Frontiers in immunology · 2024Review
- Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more.BMC infectious diseases · 2023Article
- Provision of Microbiology, Infection Services and Antimicrobial Stewardship in Intensive Care: A Survey across the Critical Care Networks in England and Wales.Antibiotics (Basel, Switzerland) · 2023Article
- Pushing the boundaries of innovation: the potential ofFrontiers in cardiovascular medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis mortality has improved following advancements in early recognition and standardized management, including emphasis on early administration of appropriate antimicrobials. However, guidance regarding antimicrobial duration in sepsis is surprisingly limited. Decreased antibiotic exposure is associated with lower rates of de novo resistance development, Clostridioides difficile-associated disease, antibiotic-related toxicities, and health care costs. Consequently, data weighing safety versus adequacy of shorter treatment durations in sepsis would be beneficial. We provide a narrative review of evidence to guide antibiotic duration in sepsis. Evidence is significantly limited by noninferiority trial designs and exclusion of critically ill patients in many trials. Potential challenges to shorter antimicrobial duration in sepsis include inadequate source control, treatment of multidrug-resistant organisms, and pharmacokinetic alterations that predispose to inadequate antimicrobial levels. Additional studies specifically targeting patients with clinical indicators of sepsis are needed to guide measures to safely reduce antimicrobial exposure in this high-risk population while preserving clinical effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.